Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Takehiro Ono"'
Publikováno v:
Fusion Engineering and Design. 192:113607
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9b8356aa359b071a08a03e4e323291d
https://doi.org/10.1016/j.fusengdes.2023.113607
https://doi.org/10.1016/j.fusengdes.2023.113607
Autor:
Masaru Sakai, Tetsuya Hagio, Tetsuya Yasuhiro, Sho Kouyama, Hidenori Miyata, Yasuo Yonetomi, Shinya Sakimoto, Takehiro Ono, Seishi Katsumata, Takashi Sasamura
Publikováno v:
Stroke. 50
Introduction: Factor XI (FXI) is an important component in the intrinsic pathway of the coagulation system. FXI antisense oligonucleotide achieves antithrombotic efficacy with a low risk of bleeding in preclinical and early clinical studies. ONO-8610
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddcd37c2f82a5526f5f857b41d145a83
https://doi.org/10.1161/str.50.suppl_1.wp336
https://doi.org/10.1161/str.50.suppl_1.wp336
Autor:
Masashi Gohda, Kenji Tanaka, Hiromu Habashita, Sho Koyama, Tetsuya Hagio, Kazuhito Kawabata, Akira Imagawa, Hidekazu Matsuya, Masaru Sakai, Yasushi Hirota, Yasuo Yonetomi, Taihei Nishiyama, Ai Hashimoto, Takehiro Ono, Shinya Sakimoto
Publikováno v:
Stroke. 48
Background and Purpose: High levels of blood coagulation factor XI (FXI) are an established risk factor for acute ischemic stroke and thrombosis. Patients with severe FXI deficiency have a low risk of ischemic stroke. In addition, FXI-deficient or an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca4b9560ce067c52f374502935a224f3
https://doi.org/10.1161/str.48.suppl_1.wp286
https://doi.org/10.1161/str.48.suppl_1.wp286
Autor:
Takehiro Ono, Miho Sakai, Hirohito Tsubouchi, Hisatoshi Ino, Eiichi Gohda, Chizuko Yukizaki, Hirofumi Uto, Kaori Hiramatsu, Yohsuke Matsumoto, Yoshihiro Sugiura, Isao Akagi, Tomoe Tsuji
Publikováno v:
Cytokine. 46(1):119-126
Hepatocyte growth factor (HGF) is useful as a potential therapeutic agent for hepatic and renal fibrosis and cardiovascular diseases through inducing proliferation of epithelial and endothelial cells. HGF inducers may also be useful as therapeutic ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7097ea6fd6ce5e5da7823eeda9502ee
https://ousar.lib.okayama-u.ac.jp/48122
https://ousar.lib.okayama-u.ac.jp/48122
Publikováno v:
Publications of the Astronomical Society of Japan. 51:91-94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7dbe07eceebedea12b968c35585b07a
https://doi.org/10.1093/pasj/51.1.91
https://doi.org/10.1093/pasj/51.1.91
Autor:
Tetsuya Hagio, Sho Koyama, Keizo Suzuki, Ai Hashimoto, Kenji Tanaka, Yasushi Hirota, Kazuhito Kawabata, Hidekazu Matsuya, Taihei Nishiyama, Masaru Sakai, Masashi Gohda, Takehiro Ono, Akira Imagawa, Takashi Kondo
Publikováno v:
Blood. 124:1542-1542
Introduction: Congenital human blood coagulation factor XI (FXI) deficiency is associated with bleeding that is less severe than that observed in patients with other coagulation factor deficiencies, whereas severe FXI deficiency confers the decreased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae7f73a2736763bf7318562c62b9ffd8
https://doi.org/10.1182/blood.v124.21.1542.1542
https://doi.org/10.1182/blood.v124.21.1542.1542